<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863016</url>
  </required_header>
  <id_info>
    <org_study_id>HEPHAESTUS_020713</org_study_id>
    <nct_id>NCT02863016</nct_id>
  </id_info>
  <brief_title>Effects of Postdilution Online Hemodiafiltration AcEtate-free Citrate dialySis Fluid on Inflammation Markers in TUscan Prevalent Hemodialysis patientS</brief_title>
  <acronym>HEPHAESTUS</acronym>
  <official_title>tHe Effects of Postdilution Online Hemodiafiltration With AcEtate-free Citrate dialySis Fluid on Inflammation Markers in TUscan Prevalent Hemodialysis patientS: HEPHAESTUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Maria Annunziata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Versilia Lido di Camaiore Lucca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Campo di Marte Lucca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Santa Maria Annunziata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effect and timing of action on the inflammatory
      state of a acetate-free containing citrate concentrate (Cit-, 1 mM Citrate) in online
      postidultion HDF with high volumes compared to traditional concentrated (Ac-, 3 mM of acetate
      ) in the medium term. In addition, the study will evaluate other parameters of efficiency
      dialysis, cardiovascular stability, the safety of the concentrate with regard to bone
      metabolism and vessel calcification in the medium term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to evaluate if a hemodiafiltration with concentrated
      citrate (Cit-HDF) in 3 months can reduce the inflammation markers, evaluated by a Predialytic
      value of Beta2-microglobulin (B2m), CRP and IL6 compared to traditional concentrated acetic
      acid (Ac-HDF).

      The secondary objectives of this study are to evaluate if Cit-HDF, compared to Ac-HDF, can
      have an effect in a period of 3 months on the following aspects:

        -  the change weekly pre-dialysis values of other markers of oxidative stress (TAC, NF-kB);

        -  the technical parameters of HDF treatment, such as convective volumes, and blood
           pressure in the circuit in the filter (TMP, pressure pre-filter);

        -  the cardiovascular stability through blood pressure and heart rate before and after
           dialysis (SBP, DBP, HR) and number of intradialytic hypotension;

        -  the parameters of safety as the variation of the values of the mobility Predialytic bone
           (PTH, alkaline phosphatase, fetuin-A), the variation of the values intradialytic
           biochemical impacted by citrate (total and ionized calcium, bicarbonate) and clotting
           time (aPTT);

        -  the variation of calcifications observed by:

             -  the expression of molecules that express the ability of calcification of muscle
                cells and endothelial cells in culture with plasma taken at the beginning of
                treatment

             -  a measure of carotid intimal thickness and pulse vawe velocity by Eco Color Doppler
                (optional);

        -  dialysis efficiency by varying pre-and post-dialysis (RR%) and Clearance average
           molecular weight solutes with small and medium (Phosphorus, Beta2 Micro, Myoglobin) and
           indices of dialysis adequacy of small molecules such as EKT / V based on the dialysance
           ion formula Watson (calculated automatically by the monitor to dialysis);
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>Value of Beta2-microglobulin (mg/l)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialytic dose</measure>
    <time_frame>3 months</time_frame>
    <description>Values of eKT / V</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Concentrate SelectBag One</arm_group_label>
    <description>Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentrate SelectBag Citrate</arm_group_label>
    <description>Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SelectBag One</intervention_name>
    <description>Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.</description>
    <arm_group_label>Concentrate SelectBag One</arm_group_label>
    <arm_group_label>Concentrate SelectBag Citrate</arm_group_label>
    <other_name>SelectBag Citrate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients clinically stable.

          -  age&gt; 18.

          -  HDF in renal replacement therapy for more than 1 month.

          -  good functionality of the vascular blood flow that allows real at least 250 ml / min.
             and recirculation below 10%.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        . Patients clinically stable.

          -  age&gt; 18.

          -  HDF in renal replacement therapy for more than 1 month.

          -  good functionality of the vascular blood flow that allows real at least 250 ml / min.
             and recirculation below 10%.

        Exclusion Criteria:

          -  Life expectancy &lt;3 months.

          -  With residual renal function&gt; 500 ml / day.

          -  Vascular access with CVC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Pizzarelli, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Santa Maria Annunziata_ Firenze (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Pizzarelli, Dr</last_name>
    <phone>+39 348 3518416</phone>
    <email>fpizzarelli@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Pizzarelli</last_name>
    <phone>+39 348 3518416</phone>
    <email>fpizzarelli@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Santa Maria Annunziata</name>
      <address>
        <city>Firenze</city>
        <state>Fi</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pizzarelli, DR</last_name>
      <phone>+39 348 3518416</phone>
      <email>fpizzarelli@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Alberto Rosati, Dr</last_name>
    </contact_backup>
    <investigator>
      <last_name>Vincenzo Panichi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Maduell F, Moreso F, Pons M, Ramos R, Mora-Maci√† J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Feb;24(3):487-97. doi: 10.1681/ASN.2012080875. Epub 2013 Feb 14. Erratum in: J Am Soc Nephrol. 2014 May;25(5):1130.</citation>
    <PMID>23411788</PMID>
  </reference>
  <reference>
    <citation>Panichi V., Bernabini G., Fanelli R., Rosati A., Pizzarelli F. Emodiafiltrazione (HDF) on line in post-diluizione con un nuovo concentrato acido a base di citrato: risultati di uno studio pilota multicentrico. Atti Convegno SIN, Genova, 2011</citation>
  </reference>
  <reference>
    <citation>Matsuyama K, Tomo T, Kadota J. Acetate-free blood purification can impact improved nutritional status in hemodialysis patients. J Artif Organs. 2011 Jun;14(2):112-9. doi: 10.1007/s10047-010-0551-7. Epub 2011 Feb 19.</citation>
    <PMID>21336818</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Maria Annunziata</investigator_affiliation>
    <investigator_full_name>Francesco Pizzarelli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dialysis</keyword>
  <keyword>hemodiafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

